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BACKGROUND Little uniformity exists in the clinical and histologic variables reported with primary Merkel
cell carcinoma (MCC).
OBJECTIVE To provide a rigorous descriptive analysis of a contemporary cohort and promote the
prospective collection of detailed data on MCC for future outcome studies.
METHODS AND MATERIALS A detailed descriptive analysis was performed for clinical and histologic
features of 147 patients with 150 primary MCC tumors in a prospectively collected database from 2006 to 2010.
RESULTS The majority (73.5%) of patients were at American Joint Committee on Cancer clinical stage I or II
at presentation, 20.4% at stage III, and 6.1% at stage IV. Detailed descriptive clinical and histologic findings are
presented.
CONCLUSION Clinical and histologic profiling of primary MCC in the literature is variable and limited.
Systematic prospective collection of MCC data is needed for future outcome studies and the ability to compare
and share data from multiple sources for this relatively rare tumor.
The authors have indicated no significant interest with commercial supporters.
Merkel cell carcinoma (MCC) is a potentiallyaggressive malignancy of the skin. With
overall 2-year disease-specific mortality estimated at
28%, MCC has a poorer prognosis than melanoma.1
Although rare, the incidence of MCC has tripled in
the past 2 decades and continues to increase,
generating greater attention for this malignancy.2
Various clinical, histologic, and immunohistochem-
ical features have been considered as prognostic
indicators. In addition to clinical tumor diameter
and presence of metastases, other factors are
emerging that may be important in predicting
prognosis. Results have been mixed; although recent
studies report a positive association between tumor
thickness, lymphovascular invasion, and infiltrative
histologic growth pattern and poor outcome,3–5
there is little uniformity in the clinical and histologic
parameters reported with a diagnosis of a primary
MCC, making it difficult to compare studies and
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examine potential prognostic variables. Further-
more, small sample sizes, attributable to this
uncommon diagnosis, negatively affect the power of
these studies and support the need for the collection
of uniform data that may be shared
across institutions.
Our purpose was to report a detailed descriptive
analysis of prospectively collected clinical and his-
tologic features in a contemporary cohort. Stan-
dardization of MCC data collected also provides an
optimal framework for future outcome studies and
the comparison and sharing of data.
Methods
Patients
The Institutional Review Board at the University of
Michigan approved this study. Our prospective
MCC database was queried for patients diagnosed
with a primary MCC who underwent consultation
in the Multidisciplinary MCC Program at the
University of Michigan between February 2006 and
March 2010. This identified 147 patients with a
diagnosis of a new primary MCC. One patient
developed a second primary MCC in the study
period, and two had had a previous diagnosis of
primary MCC in 2000 and 2001. Histopathology
was reviewed for diagnostic confirmation by a
dermatopathologist at the University of Michigan. A
profile, including the histopathologic features below,
was reported for each primary MCC.6
Variables
Clinical variables included patient sex, age, race,
presence or absence of immunosuppression (medi-
cation- or disease-induced immunosuppression),
history of other skin cancer (yes/no), history of other
non-skin cancer (yes/no), site of the primary MCC
(head or neck, trunk, arm, hand, leg or buttock, or
foot), and clinical size (<1, 1–2, >2 cm). If the tumor
was present at consultation, the faculty physician
measured it. Otherwise, the size from the referring
physician was recorded, or when not available, size
was estimated using patient description, biopsy scar,
or gross pathology description. Patients were staged
at presentation according to the American Joint
Committee on Cancer (AJCC) Seventh Edition (stage
I, cutaneous disease only,  2 cm maximum tumor
dimension; stage II, cutaneous disease only, >2 cm
maximum tumor dimension; stage III, regional
lymph node or in transit disease; stage IV, distant
disease).7 Clinical size was used for maximum
tumor dimension.
Histopathologic variables included greatest histo-
logic horizontal dimension within a transversely
serially sectioned specimen (measured in millimeter),
tumor thickness (measured in mm from the granular
layer of the epidermis to the deepest extent of tumor
invasion; Breslow depth), anatomic level of invasion
(Clark level), number of mitoses per square milli-
meter, tumor growth pattern (circumscribed or
infiltrative), and presence or absence of ulceration
and angiolymphatic invasion. Mitotic rate was
determined by counting the number of dermal
mitoses in 1 mm2, starting in the field with the most
mitoses. Mitotic rate was not included in the profile
during initial accrual stages but was subsequently
added to the profile. Tumors with a circumscribed
growth pattern demonstrated well-circumscribed
tumor nodules with pushing borders. An infiltrative
growth pattern was characterized by strands, cords,
trabeculae, and single cells of tumor infiltrating
dermal collagen or soft tissue. Tumors displaying
both patterns were classified as infiltrative.
Results
One hundred forty-seven patients were identified.
Three had two primary tumors, for a total of 150
primary MCCs in this cohort. Seventy women
(47.6%) and 77 (52.4%) men were identified.
Patient characteristics are reported in Table 1 (age,
race, immunosuppression status, history of non-
MCC skin cancer and non-skin cancer, and clinical
and pathologic stage at presentation). Sentinel
lymph node biopsy was performed for pathologic
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staging in 98 of 108 (90.7%) patients presenting
with localized skin MCC, which upstaged 41
(38.0%) patients.
Fourteen (9.5%) patients were immunosuppressed:
six with renal transplants, one with a lung
transplant, four with chronic lymphocyte leukemia
(CLL), and three taking immunosuppressive
medication for other reasons (idiopathic pulmonary
fibrosis, ulcerative colitis, rheumatoid arthritis).
All immunosuppressed patients were Caucasian
(8 male, 6 female). The mean age of presentation
in these patients was 59.6, compared with
71.4 years in immunocompetent patients. Eighty-
one (55.1%) patients reported a history of other
cancer types, skin and non-skin, at the time of
presentation (Table 2).
Main tumor characteristics, including histopathol-
ogy features, are reported in Table 3. Some charac-
teristics had a smaller total number than the 150
total tumors because of nonstandardized histopa-
thology in a minority of cases early in the study time
period.
In 64 of 148 primary lesions (43.2%), clinical size
was obtained by measuring the lesion at consultation
at the University of Michigan, 28 (18.9%) were
determined from the referring physician’s descrip-
tion, 48 (32.4%) were estimated based on scar or
patient description, 7 (4.7%) were obtained
according to gross pathology description, and the
source of clinical size measurement was unknown
for one lesion. Lesions of <1 cm were more likely to
be on the head and neck (64.9%, 37/57) than in
other locations, but lesions 1 cm or more in clinical
diameter were more common in other locations
(67%, 61/91) than on the head and neck.
Discussion
Although the incidence of MCC is lower than with
other cutaneous malignancies, the increasing
incidence and potentially aggressive nature have
directed attention toward this cancer. In this study,
patient and tumor features were examined for the
purpose of a detailed descriptive analysis from a
contemporary, prospectively collected, single-
institution database.
TABLE 1. Characteristics of 147 Patients With
Primary Merkel Cell Carcinoma (MCC)
Characteristic Value
Age, mean (range) 70.3 (38–91)
Race, n (%)
Caucasian 145 (98.6)
African American 2 (1.4)
Immunosuppressed, n (%)
Yes 14 (9.5)
No 133 (90.5)
History of non-MCC skin cancer, n (%)
Yes 64 (43.5)
No 83 (56.5)
History of non-skin cancer, n (%)
Yes 28 (19.0)
No 119 (81.0)
Clinical stage at presentation, n (%)
I 80 (54.4)
II 28 (19.0)
III 30 (20.4)
IV 9 (6.1)
Pathologic stage at presentation, n (%)
I 55 (37.4)
II 12 (8.2)
III 71 (48.3)
IV 9 (6.1)
TABLE 2. Summary of Other Cancer Types in
Patients With Merkel Cell Carcinoma
Cancer Type n (%)
Skin
Basal cell carcinoma 48 (32.7)
Squamous cell carcinoma including
in situ
31 (21.1)
Melanoma including in situ 8 (5.4)
Non-skin
Lymphoma 6 (4.1)
Prostate 5 (3.4)
Breast 5 (3.4)
Chronic lymphocytic leukemia 4 (2.7)
Lung 4 (2.7)
Renal cell carcinoma 2 (1.4)
Thyroid 1 (0.7)
Bladder 1 (0.7)
Fallopian tube 1 (0.7)
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Clinical Characteristics
Many clinical characteristics were similar to those
reported in other studies. The majority of patients
diagnosed with MCC are older Caucasians.8–14 The
mean age at diagnosis in our study was 70.3. Our
data suggested a minimal male to female predomi-
nance of 1.1:1, compared with that reported by
Heath and colleagues of 1.4:1.10 In our study,
45.3% of lesions occurred on the head and neck and
50.0% on the extremities, including the buttocks.
Others have reported frequencies of 29 to 62.5% on
the head and neck and 33 to 52% on the extremities,
including the buttocks.10,11,13
In our study, 9.5% of patients were immunosup-
pressed. Numerous studies support an association
between MCC and immunosuppression. Medina-
Franco and colleagues, in a review of seven studies,
reported that 14.5% of patients had received or
were receiving immunosuppressive therapy, and
Heath and colleagues reported that 7.8% of their
cohort were profoundly immunosuppressed (human
immunodeficiency virus, chronic lymphocytic leu-
kemia (CLL), solid organ transplant).10,13 Observa-
tions of MCC in transplant patients and patients
with autoimmune disease taking immunosuppres-
sant drugs indicate that long-term iatrogenic immu-
nosuppression increases the risk of MCC.15 In the
study by Heath and colleagues, age at diagnosis was
comparable in immunosuppressed and immuno-
competent patients,10 but in our study, immuno-
suppressed patients were on average more than
10 years younger than immunocompetent patients
at diagnosis. In organ transplant patients, the mean
age at diagnosis has been reported as 53.16
Other malignancies have been identified with a high
incidence in individuals with MCC. According to
Howard and colleagues, in patients with other first
primary cancers, the risk of developing MCC as a
second primary malignancy was 1.36 times as
great.17 In our study, 55.1% of patients had a
diagnosis of a non-MCC cancer before diagnosis of
MCC. History of a non-MCC skin cancer, including
basal cell carcinoma (BCC), squamous cell carci-
noma (SCC), and melanoma, occurred in 43.5% of
patients. BCC occurred most commonly, followed
by SCC and then melanoma. Others have also found
a high incidence of skin cancers in patients with
MCC.13,18,19 In our cohort, 21.1% of patients had a
history of SCC, somewhat lower than the 34 to 41%
in other reports that, unlike our study, included SCC
after presentation of MCC.19–21 Twenty-eight
(19.0%) patients had a diagnosis of a non-skin
cancer before diagnosis of MCC. Ten patients were
diagnosed with a hematologic malignancy,
TABLE 3. Tumor Characteristics of 150 Primary
Merkel Cell Carcinomas
Characteristic Value
Location, n (%)
Head and neck 68 (45.3)
Lower extremity and buttock 36 (24.0)
Upper extremity 30 (20.0)
Trunk 7 (4.7)
Hand 7 (4.7)
Foot 2 (1.3)
Clinical size, cm, n (%)
<1 57 (38.0)
1—2 48 (32.0)
>2 43 (28.7)
Not specified 2 (1.3)
Tumor thickness, mm (n = 130)
Mean (range) 6.4 (0.3–25)
Median 5
Anatomic level of invasion (n = 132), n (%)
II 1 (0.8)
III 3 (2.3)
IV 56 (42.4)
V 72 (54.5)
Mitotic rate per mm2 (n = 103)
Mean (range) 29 (1–96)
Greatest horizontal histologic dimension, mm
(n = 112)
Mean (range) 9.5 (0.8–45)
Angiolymphatic invasion (n = 136), n (%)
Present 45 (33.1)
Absent 82 (60.3)
Equivocal 9 (6.6)
Ulceration (n = 123), n (%)
Present 13 (10.6)
Absent 107 (87.0)
Equivocal 3 (2.4)
Growth pattern (n = 131), n (%)
Circumscribed 70 (53.4)
Infiltrative 61 (46.6)
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lymphoma or CLL, both of which have been
shown to carry a greater risk of MCC as a second
primary malignancy.19,22
The majority of patients with MCC (70%) present
with disease clinically limited to the skin (stage I or
II), 25% with palpable regional lymphadenopathy
(stage III), and 5% with distant metastases
(stage IV).7,11,13 The clinical staging of our patients
at presentation was similar, with 54.5% with stage I
disease, 19.0% with stage II, 20.4% with stage III,
and 6.1% with stage IV. Clinical staging results in
understaging in many patients with MCC.11 After
pathologic staging with sentinel lymph node biopsy
in more than 90% of our clinical stage I and II
patients, the pathologic staging of our patients at
presentation changed to 37.4% with stage I disease,
8.2% with stage II, 48.3% with stage III, and 6.1%
with stage IV. Furthermore, if we included 14
patients with unknown primary tumors seen in
the clinic during the study period, almost 60%
of patients with MCC had regional or distant
disease at presentation.
Tumor Characteristics
Tumor size is a dominant factor in staging, but until
recently, use of multiple staging systems has led to
confusion and inconsistencies among health care
providers, patients, and researchers.23 In late 2009,
the AJCC adopted a consensus staging system in
which the maximum dimension of the tumor plays
an important role in staging,7 but the method of
measuring is not defined and may be interpreted as
clinical (clinical size) or histologic (greatest histo-
logic horizontal dimension). In this study, three
distinct size measurements were recorded for each
primary MCC—clinical size, greatest histologic
horizontal dimension, and tumor thickness—
although it remains to be determined whether one of
these measurements is superior to the others at
predicting outcome. Historically, clinically mea-
sured sizes have been the standard, yet as in our
study, we would expect considerable variability in
how clinical size is obtained. Ideally, study physi-
cians would measure clinical size, but in referral
medical centers, a partial or complete biopsy has
often prompted patients’ referral. In these instances,
when available, we used measurements that refer-
ring physicians obtained. In other instances, we had
only patient description or biopsy scar length avail-
able, which is a suboptimal means of measurement.
In the literature, how clinical size measurement is
obtained is frequently lacking but would be expected
to be variable as well. This may have implications
for the prognostic strength of clinical size in com-
parison with the other measurements of tumor size.
Greatest histologic horizontal dimension would be
expected to underestimate clinical size in part
because of shrinkage that occurs with standard
formalin-fixed permanent section tissue process-
ing.24 In this study, the mean greatest histologic
horizontal dimension was 9.07 mm for tumors with
clinical size of 1 to 2 cm and 16.38 mm for tumors
with clinical size >2 cm. In this study, if greatest
histologic horizontal dimension rather than clinical
size was used for staging, 18 primary MCCs would
have been understaged. Tumor thickness has the
potential to be a strong prognostic indicator. Recent
studies report a positive association between greater
tumor thickness and poor outcome.3 Other studies
have found no correlation between tumor thickness
and disease-free or overall survival.25 Using mea-
surements from biopsy and re-excision if residual
tumor is present, tumor thickness may be the most
reproducible and reviewable. A consistent and
systematic way to measure and report lesion size is
critical for staging and downstream clinical
decision-making and management.
In our series, tumors were smaller than those
reported in the literature, with 38.0% of primary
lesions smaller than 1 cm, 32.0% 1 to 2 cm, and
28.7% larger than 2 cm in clinical diameter. In the
study by Heath and colleagues of patients diagnosed
with MCC between 1980 and 2007, 21.3% of
primary lesions were smaller than 1 cm, 43.3%
were 1 to 2 cm, and 35.3% were larger than 2 cm in
clinical diameter.10 Similarly, in our study, mean
greatest histologic horizontal diameter was 9.5 mm,
compared with a mean of 20.1 mm reported in a
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study of 156 patients over 25 years.3 It is likely
that, with increased awareness of MCC and skin
cancer in general, diagnosis occurs earlier in the
disease course.
Various other histologic factors included in our
primary MCC profile have been considered in
analyses of prognostic variables in the literature,
mostly small studies, including anatomic level of
invasion, mitotic rate, growth pattern, ulceration,
and angiolymphatic invasion.3–5,26–30 In 96.9% of
our patients, the primary MCC extended to ana-
tomic level IV or V, and in 54.5%, the tumor
involved the subcutis (level V). In a study by Andea
and colleagues, the deepest anatomic compartment
involved by tumor was significantly associated with
survival.3 Some smaller studies support this, but
others do not.27,29,30
Few studies report on mitotic rate in primary
MCC. In this study, the mean mitotic rate was 29/
mm2 (range 1–96/mm2). Skelton and colleagues
found that higher mitotic rates were associated
with lower survival rates, but two smaller studies
failed to show a correlation.28–30 Our prior study
found that greater mitotic rate was significantly
associated with greater likelihood of a positive
sentinel lymph node in MCC.31
In our cohort, 53.4% of tumors had a circumscribed
growth pattern, and 46.6% had an infiltrative
pattern. Histologic growth pattern has been shown
to have prognostic significance in some studies.3,29
Andea and colleagues reported that a circumscribed
pattern was associated with longer survival, whereas
an infiltrative pattern had a poorer prognosis.3 We
previously reported that an infiltrative pattern was
significantly associated with a greater likelihood of a
positive sentinel lymph node.31 Several small studies
have not shown significance of histologic growth
pattern as a prognostic marker in MCC.28,30
Ulceration was present in only 10.6% of primary
MCCs in this cohort. Similarly, Andea and col-
leagues reported ulceration in 8% of their patients.3
Ulceration has not been shown to correlate
significantly with prognosis.3,28–30
Angiolymphatic invasion has been reported to occur
in 30 to 60% of MCCs and, in our study, occurred
in 33.1%.3–5,28–30 In the study by Fields and
colleagues, lymphovascular invasion was present in
56% of the primary tumors in which the status was
reported.4 The discrepancy in the percentage of
tumors with lymphovascular invasion between the
study by Fields and colleagues and our study may be
attributable to the use of immunohistochemistry in
the former study to evaluate for angiolymphatic
invasion in tumors initially found to be negative on
hematoxylin and eosin evaluation. Andea and col-
leagues found lymphovascular invasion to be an
independent predictor of survival on multivariate
analysis, and in the study by Fields and colleagues,
the presence of lymphovascular invasion was sig-
nificantly associated with greater disease-specific
death.3,4 Other studies have failed to show a
significant correlation between angiolymphatic
invasion and survival.28–30
TABLE 4. Clinical and Histologic Variables for Prospective Documentation in Primary Merkel Cell Carcinoma
Clinical Variables Histologic Variables
Sex Greatest histologic horizontal dimension
(in a transversely serially sectioned specimen)
Age Tumor thickness (Breslow depth)
Race Anatomic level of invasion (Clark level)
Immunosuppression status Mitoses per mm2 (number of dermal mitoses in one mm2)
History of other cancers Tumor growth pattern (circumscribed or infiltrative)
Clinical and pathologic stage at presentation Ulceration
Tumor site Angiolymphatic invasion
Tumor clinical size (greatest diameter)
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Conclusion
This study presents a cross-sectional analysis of a
modern prospectively maintained database with
consistent pathology review. Histopathologic pro-
filing of primary MCC in the literature is variable
and limited, yet the importance of an accurate
histopathologic profile for primary MCC cannot be
overstated.6,32 Prospective documentation of these
histologic parameters and clinical features, pre-
sented in Table 4, is needed to meaningfully analyze
these for prognostic significance and to identify the
important independent clinical and histologic fea-
tures that best predict outcome. In the future,
because of the rarity of the tumor, systematic
prospective collection of detailed MCC data can be
used to provide the framework for rigorous outcome
studies and the ability to compare and share data
from multiple sources.
References
1. The Rockville Merkel Cell Carcinoma Group. Merkel cell
carcinoma: recent progress and current priorities on etiology,
pathogenesis, and clinical management. J Clin Oncol
2009;27:4021–4026.
2. Hodgson NC. Merkel cell carcinoma: changing incidence trends. J
Surg Oncol 2005;89:1–4.
3. Andea AA, Coit DG, Amin B, Busam KJ. Merkel cell carcinoma:
histologic features and prognosis. Cancer 2008;113:2549–2558.
4. Fields RC, Busam KJ, Chou JF, Panageas KS, et al. Five hundred
patients with Merkel cell carcinoma evaluated at a single
institution. Ann Surg 2011;254:465–473.
5. Fields RC, Busam KJ, Chou JF, Panageas KS, et al. Recurrence
and survival in patients undergoing sentinel lymph node biopsy
for Merkel cell carcinoma: analysis of 153 patients from a single
institution. Ann Surg Oncol 2011;18:2529–2537.
6. Bichakjian CK, Lowe L, Lao CD, Sandler HM, et al. Merkel cell
carcinoma: critical review with guidelines for multidisciplinary
management. Cancer 2007;110:1–12.
7. Merkel cell carcinoma. In: Edge SB, Byrd DR, Compton CC, Fritz
AG, Greene FL, Trotti A, editors. AJCC cancer staging manual.
New York, NY: Springer, 2009. pp. 315–323.
8. Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, et al.
Merkel cell carcinoma demographics, morphology, and survival
based on 3870 cases: a population based study. J Cutan Pathol
2010;37:20–27.
9. Stokes JB, Graw KS, Dengel LT, Swenson BR, et al. Patients with
Merkel cell carcinoma tumors < or = 1.0 cm in diameter are
unlikely to harbor regional lymph node metastasis. J Clin Oncol
2009;27:3772–3777.
10. Heath M, Jaimes N, Lemos B, Mostaghimi A, et al. Clinical
characteristics of Merkel cell carcinoma at diagnosis in 195
patients: the AEIOU features. J Am Acad Dermatol
2008;58:375–381.
11. Allen PJ, Bowne WB, Jaques DP, Brennan MF, et al. Merkel cell
carcinoma: prognosis and treatment of patients from a single
institution. J Clin Oncol 2005;23:2300–2309.
12. Agelli M, Clegg LX. Epidemiology of primary Merkel cell
carcinoma in the United States. J Am Acad Dermatol
2003;49:832–841.
13. Medina-Franco H, Urist MM, Fiveash J, Heslin MJ, et al.
Multimodality treatment of Merkel cell carcinoma: case series
and literature review of 1024 cases. Ann Surg Oncol
2001;8:204–208.
14. Akhtar S, Oza KK, Wright J. Merkel cell carcinoma: report of 10
cases and review of the literature. J Am Acad Dermatol
2000;43:755–767.
15. Agelli M, Clegg LX, Becker JC, Rollison DE. The etiology and
epidemiology of Merkel cell carcinoma. Curr Probl Cancer
2010;34:14–37.
16. Penn I, First MR. Merkel’s cell carcinoma in organ recipients:
report of 41 cases. Transplantation 1999;68:1717–1721.
17. Howard RA, Dores GM, Curtis RE, Anderson WF, et al. Merkel
cell carcinoma and multiple primary cancers. Cancer Epidemiol
Biomarkers Prev 2006;15:1545–1549.
18. Kaae J, Hansen AV, Biggar RJ, et al. Merkel cell carcinoma:
incidence, mortality, and risk of other cancers. J Natl Cancer Inst
2010;102:793–801.
19. Brenner B, Sulkes A, Rakowsky E, Feinmesser M, et al. Second
neoplasms in patients with Merkel cell carcinoma. Cancer
2001;91:1358–1362.
20. Walsh NM. Primary neuroendocrine (merkel cell) carcinoma of
the skin: morphologic diversity and implications thereof. Hum
Pathol 2001;32:680–689.
21. Gomez LG, DiMaio S, Silva EG, Mackay B. Association
between neuroendocrine (merkel cell) carcinoma and
squamous cell carcinoma of the skin. Am J Surg Pathol
1983;7:171–177.
22. Vlad R, Woodlock TJ. Merkel cell carcinoma after chronic
lymphocytic leukemia: case report and literature review. Am J
Clin Oncol 2003;26:531–534.
23. Sarnaik AA, Lien MH, Nghiem P, Bichakjian CK. Clinical
recognition, diagnosis, and staging of merkel cell carcinoma, and
the role of the multidisciplinary management team. Curr Probl
Cancer 2010;34:38–46.
24. Dauendorffer JN, Bastuji-Garin S, Guero S, et al. Shrinkage of
skin excision specimens: formalin fixation is not the culprit. Br J
Dermatol 2009;160:810–814.
25. Goldberg SR, Neifeld JP, Frable WJ. Prognostic value of tumor
thickness in patients with Merkel cell carcinoma. J Surg Oncol
2007;95:618–622.
26. Andea A, Coit DG, Busam K. An analysis of morphologic
parameters as prognostic markers in Merkel cell carcinoma. Am J
Dermatopathol 2006;28:228.
SCHWARTZ ET AL
39 :7 : JULY 2013 1015
27. Sandel HD 4th, Day T, Richardson MS, Scarlett M, et al. Merkel
cell carcinoma: does tumor size or depth of invasion correlate
with recurrence, metastasis, or patient survival? Laryngoscope
2006;116:791–795.
28. Llombart B, Monteagudo C, Lopez-Guerrero JA, Carda C, et al.
Clinicopathological and immunohistochemical analysis of 20
cases of Merkel cell carcinoma in search of prognostic markers.
Histopathology 2005;46:622–634.
29. Mott RT, Smoller BR, Morgan MB. Merkel cell carcinoma: a
clinicopathologic study with prognostic implications. J Cutan
Pathol 2004;31:217–223.
30. Skelton HG, Smith KJ, Hitchcock CL, McCarthy WF, et al.
Merkel cell carcinoma: analysis of clinical, histologic, and
immunohistologic features of 132 cases with relation to survival.
J Am Acad Dermatol 1997;37:734–739.
31. Schwartz JL, Griffith KA, Lowe L, Wong SL, et al. Features
predicting sentinel lymph node positivity in Merkel cell
carcinoma. J Clin Oncol 2011;29:1036–1041.
32. Brown JA, Smoller BR. Merkel cell carcinoma: what is it, what
will it do and where will it go? what role should the pathologist
play in reporting this information? J Cutan Pathol
2009;36:924–927.
Address correspondence and reprint requests to: Jennifer
L. Schwartz, MD, University of Michigan Health System,
1910 Taubman Center, 1500 E. Medical Center Dr., Ann
Arbor, MI 48109, or e-mail: jennschw@med.umich.edu
MERKEL CELL CARCINOMA
DERMATOLOGIC SURGERY1016
